| BMYMP |
Bristol-Myers Squibb Co |
92%
|
Reciprocal relationship from BMYMP graph: In April 2026, BMS entered into agreements with Dr. Reddy's Laboratories that allow for (i) an Orencia biosimilar for intravenous administration to be market… |
| BMY |
Bristol-Myers Squibb Company |
90%
|
Reciprocal relationship from BMY graph: In April 2026, BMS entered into agreements with Dr. Reddy's Laboratories that allow for (i) an Orencia biosimilar for intravenous administration to be marketed… |
| PAR-PHARMACEUTICAL-INC-SUN-PHARMACEUTICALS-LIMIT |
PAR-PHARMACEUTICAL-INC-SUN-PHARMACEUTICALS-LIMIT |
85%
|
t typically decline, in some cases significantly. Accordingly, the level of market share, revenues and gross profit attributable to a particular generic product is normally dependent upon the number … |
| FBIO |
Fortress Biotech, Inc. |
80%
|
Reciprocal relationship from FBIO graph: Journey holds global rights to Emrosi™ (Minocycline Hydrochloride Modified Release Capsules, 40 mg) pursuant to a license agreement with Dr. Reddy's Laborator… |
| AMRX |
Amneal Pharmaceuticals, Inc. |
72%
|
t typically decline, in some cases significantly. Accordingly, the level of market share, revenues and gross profit attributable to a particular generic product is normally dependent upon the number … |
| AMRX |
Amneal Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from AMRX graph: Reciprocal relationship from RDY graph: t typically decline, in some cases significantly. Accordingly, the level of market share, revenues and gross profit at… |
| DERM |
Journey Medical Corporation |
72%
|
me 5,217 5,426 5,655 License fees (2) 4,503 3,789 2,113 Rs. 335,933 Rs. 325,535 Rs. 279,164 (1) For the year ended March 31, 2026, consequent to resolution of a shelf stock adjustment claim arising f… |
| DERM |
Journey Medical Corporation |
72%
|
Reciprocal relationship from DERM graph: Reciprocal relationship from RDY graph: Reciprocal relationship from DERM graph: Reciprocal relationship from RDY graph: me 5,217 5,426 5,655 License fees (2)… |
| IMMP |
Immutep Limited |
72%
|
Reciprocal relationship from IMMP graph: Reciprocal relationship from RDY graph: th rate considered does not exceed that of the relevant business and industry sector. d) The post-tax discount rates a… |
| IMMP |
Immutep Limited |
72%
|
th rate considered does not exceed that of the relevant business and industry sector. d) The post-tax discount rates and pre-tax discount rates used for the Active Pharmaceutical Operations CGU and t… |
| NVSEF |
Novartis AG |
72%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from RDY graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from RDY graph: Reciprocal relationship from NVSEF … |
| NVSEF |
Novartis AG |
72%
|
ell lung cancer following the results of the futility analysis. As a result, the Company recorded an impairment loss of Rs. 914 (U.S.$ 10 ) in the consolidated income statements forming part of the G… |
| SNYNF |
Sanofi |
72%
|
last assignment with Sanofi was to divest the European generic business in October 2018, now known as Zentiva. Mr. Aghanian has experience spanning originator, consumer health and generic pharmaceuti… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from RDY graph: last assignment with Sanofi was to divest the European generic business in October 2018, now known as Zentiva. Mr. Ag… |
| TEVJF |
Teva Pharmaceutical Industries Limited |
72%
|
h we acquired from Haleon UK Enterprises Limited (the “Acquired NRT Business”). In addition, through distribution partners we access our portfolio of hospital customers. These markets include Austria… |
| TEVJF |
Teva Pharmaceutical Industries Limited |
72%
|
Reciprocal relationship from TEVJF graph: Reciprocal relationship from RDY graph: Reciprocal relationship from TEVJF graph: Reciprocal relationship from RDY graph: h we acquired from Haleon UK Enterp… |
| XYF |
X Financial |
72%
|
last assignment with Sanofi was to divest the European generic business in October 2018, now known as Zentiva. Mr. Aghanian has experience spanning originator, consumer health and generic pharmaceuti… |
| XYF |
X Financial |
72%
|
Reciprocal relationship from XYF graph: Reciprocal relationship from RDY graph: Reciprocal relationship from XYF graph: Reciprocal relationship from RDY graph: Reciprocal relationship from XYF graph:… |
| ACCORD-HEALTHCARE-LIMITED |
ACCORD-HEALTHCARE-LIMITED |
62%
|
025 we have filed a cumulative total of six New Drug Submission (“NDS”), one Drug Identification Number (“DIN-A”) Application, 80 Abbreviated New Drug Submissions (“ANDS”) and one Class III Natural H… |
| AURIGENE-DISCOVERY-TECHNOLOGIES-LIMITED |
AURIGENE-DISCOVERY-TECHNOLOGIES-LIMITED |
62%
|
2020, we carved out our discovery service business from Aurigene Oncology Limited (“AOL”) (formerly Aurigene Discovery Technologies Limited) and our contract development and manufacturing services bu… |
| AURIGENE-ONCOLOGY-LIMITED |
AURIGENE-ONCOLOGY-LIMITED |
62%
|
2020, we carved out our discovery service business from Aurigene Oncology Limited (“AOL”) (formerly Aurigene Discovery Technologies Limited) and our contract development and manufacturing services bu… |
| AUROBINDO-PHARMA-LIMITED |
AUROBINDO-PHARMA-LIMITED |
62%
|
t typically decline, in some cases significantly. Accordingly, the level of market share, revenues and gross profit attributable to a particular generic product is normally dependent upon the number … |
| BERLIN-CHEMIE-MENARINI-PHARMA-GMBH-KRKA-PHARMA-L |
BERLIN-CHEMIE-MENARINI-PHARMA-GMBH-KRKA-PHARMA-L |
62%
|
safer locations and continue to fulfill their responsibilities in hybrid format depending on local safety consideration. We continue to ensure availability of our products in these markets. Managemen… |
| CIPLA-LIMITED-GLAXOSMITHKLINE-PHARMACEUTICALS-LI |
CIPLA-LIMITED-GLAXOSMITHKLINE-PHARMACEUTICALS-LI |
62%
|
. 31 While the degree of regulation in certain markets may impact product development, we are observing increasing convergence of development needs throughout both highly regulated and less regulated… |
| EMCURE-PHARMACEUTICALS-LIMITED |
EMCURE-PHARMACEUTICALS-LIMITED |
62%
|
. 31 While the degree of regulation in certain markets may impact product development, we are observing increasing convergence of development needs throughout both highly regulated and less regulated… |
| ENDO-PHARMACEUTICALS-INC |
ENDO-PHARMACEUTICALS-INC |
62%
|
t typically decline, in some cases significantly. Accordingly, the level of market share, revenues and gross profit attributable to a particular generic product is normally dependent upon the number … |
| FRESENIUS-KABI-SAGENT-PHARMACEUTICALS-AMNEAL-PHA |
FRESENIUS-KABI-SAGENT-PHARMACEUTICALS-AMNEAL-PHA |
62%
|
t typically decline, in some cases significantly. Accordingly, the level of market share, revenues and gross profit attributable to a particular generic product is normally dependent upon the number … |
| GLENMARK-PHARMACEUTICALS-LIMITED-MANKIND-PHARMA- |
GLENMARK-PHARMACEUTICALS-LIMITED-MANKIND-PHARMA- |
62%
|
. 31 While the degree of regulation in certain markets may impact product development, we are observing increasing convergence of development needs throughout both highly regulated and less regulated… |
| HALEON-UK-ENTERPRISES-LIMITED |
HALEON-UK-ENTERPRISES-LIMITED |
62%
|
025 we have filed a cumulative total of six New Drug Submission (“NDS”), one Drug Identification Number (“DIN-A”) Application, 80 Abbreviated New Drug Submissions (“ANDS”) and one Class III Natural H… |
| KUNSHAN-ROTAM-REDDY-PHARMACEUTICALS-COMPANY-LIMI |
KUNSHAN-ROTAM-REDDY-PHARMACEUTICALS-COMPANY-LIMI |
62%
|
nt venture called Kunshan Rotam Reddy Pharmaceuticals Company Limited (“KRRP”) has commercialized several products. Some of these products are manufactured by KRRP at its manufacturing plant in Kunsh… |
